Edwards Lifesciences Corp (EW)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	4,174,600	4,158,900	1,473,000	1,413,800	1,402,400	1,430,900	1,389,500	1,488,800	1,521,900	1,458,800	1,455,400	1,538,500	1,503,100	1,477,300	1,462,400	851,000	823,400	794,100	743,600	1,107,800
Total stockholders’ equity	US$ in thousands	9,998,400	9,545,600	7,437,400	7,117,900	6,650,000	6,657,500	6,375,700	5,978,000	5,806,700	6,217,800	5,943,600	5,844,900	5,835,900	5,541,300	5,133,300	4,658,400	4,574,300	4,210,300	3,839,100	3,901,100
ROE		41.75%	43.57%	19.81%	19.86%	21.09%	21.49%	21.79%	24.90%	26.21%	23.46%	24.49%	26.32%	25.76%	26.66%	28.49%	18.27%	18.00%	18.86%	19.37%	28.40%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $4,174,600K ÷ $9,998,400K
= 41.75%

Edwards Lifesciences Corp's return on equity (ROE) has shown fluctuations over the periods indicated. The ROE was relatively high at 28.40% as of March 31, 2020, but then experienced a decline and ranged between 18% to 19% throughout 2020 and early 2021.

However, there was a significant improvement in ROE in the second quarter of 2021, reaching 28.49%, which was one of the highest levels recorded during the data period. The high ROE level was sustained through the third quarter of 2021 at 26.66% and the fourth quarter at 25.76%.

Subsequently, the ROE fluctuated within the range of 21% to 26% from the first quarter of 2022 to the first quarter of 2024, with some periods showing slight declines and recoveries.

Notably, there was a substantial increase in the ROE in the third quarter of 2024, reaching 43.57%, followed by a slightly lower ROE of 41.75% in the fourth quarter of 2024.

Overall, Edwards Lifesciences Corp's ROE demonstrates variability over time, with periods of both highs and lows. Investors and stakeholders should consider the company's performance and financial strategies in relation to its ROE trends to gain a comprehensive understanding of its profitability and efficiency in generating returns for shareholders.